■回顾阵发性室上性心动过速(PSVT)的治疗方案和更新。
■对PubMed进行了文献检索,包括1974年至2023年6月的文章,使用以下术语:心律失常,腺苷,维拉帕米,地尔硫卓,艾司洛尔,普萘洛尔,美托洛尔,β受体阻滞剂,胺碘酮,PSVT,同步心脏复律,甲基黄嘌呤,双嘧达莫,儿科,心脏移植,和怀孕。回顾了主要文献和指南。
■如果研究以英语提供并在人类中进行,则考虑了这些研究。
■PSVT是室上性心动过速(SVT)的一个子集,有规律的心动过速突然发作和终止。由于频繁的急诊科(ED)每年都会出现PSVT的症状,对这些患者进行适当和有效的管理至关重要。这篇综述概述了PSVT的病理生理学。同时还描述了PSVT的非药物和药物管理背后的文献。
■这篇综述描述了关于改良Valsalva手法作为PSVT非药物治疗的改善成功率的新文献。此外,它描述了一种腺苷给药的新技术,改善了结果,定义药物与腺苷相互作用所需的剂量调整,比较非二氢吡啶类钙通道阻滞剂与腺苷的使用,并为特殊人群的患者提供管理建议。
■室上性心动过速很高,提供者应了解基于患者特定因素的治疗管理和修改背后的数据(即,患者偏好,药代动力学/药效学,药物相互作用,和特殊人群)。
UNASSIGNED: To
review treatment options and updates that exist for the management of paroxysmal supraventricular tachycardia (PSVT).
UNASSIGNED: A literature search of PubMed was performed including articles from 1974 to June 2023 using the terms: arrhythmias, adenosine, verapamil, diltiazem, esmolol, propranolol, metoprolol, beta-blockers, amiodarone, PSVT, synchronized cardioversion, methylxanthines, dipyridamole, pediatrics, heart transplant, and pregnancy. Primary literature and guidelines were reviewed.
UNASSIGNED: Studies were considered if they were available in English and conducted in humans.
UNASSIGNED: PSVT is a subset of supraventricular tachycardia (SVT) that presents as a rapid, regular tachycardia with an abrupt onset and termination. Due to frequent emergency department (ED) visits annually with symptoms of PSVT, appropriate and efficient management of these patients is vital. This
review provides an overview of the pathophysiology of PSVT, while also describing the literature behind nonpharmacologic and pharmacologic management of PSVT.
UNASSIGNED: This
review describes new literature regarding the improved success of the modified Valsalva maneuver as a nonpharmacologic therapy in PSVT. In addition, it describes a new technique in administration of adenosine that has improved outcomes, defines dose adjustments needed for drug interactions with adenosine, compares the utilization of nondihydropyridine calcium channel blockers with adenosine, and provides management recommendations for patients in special populations.
UNASSIGNED: With high annual rates of ED visits for SVT, providers should be aware of the data behind management and modifications of therapy based on patient-specific factors (ie, patient preference, pharmacokinetics/pharmacodynamics, drug interactions, and special populations).